IL13 and asthma: Both are characterized by type 2 inflammation, with the highest levels of IL-5, IL-13, and IL-10, suggesting that these clusters reflect asthma endotypes that might be particularly suitable for biologics, such as mepolizumab30 and lebrikizumab,31 that currently use indirect biomarkers (ie, eosinophil counts and serum periostin levels) to select patients to maximize clinical efficacy.